CervoMed(CRVO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CRVO CervoMed

Trading 12-08 12:15:50 EST

8.73

+0.04

+0.40%

High8.93	Low8.62	Vol17.29K
Open8.69	D1 Closing8.69	Amplitude3.57%
Mkt Cap80.73M	Tradable Cap43.05M	Total Shares9.25M
T/O151.91K	T/O Rate0.35%	Tradable Shares4.93M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CRVO","market":"US","secType":"STK","nameCN":"CervoMed","latestPrice":8.725,"timestamp":1765214115873,"preClose":8.69,"halted":0,"volume":17285,"delay":0,"floatShares":4934300,"shares":9252719,"eps":-2.873156,"marketStatus":"Trading","change":0.035,"latestTime":"12-08 12:15:50 EST","open":8.69,"high":8.93,"low":8.6201,"amount":151914.56356500002,"amplitude":0.035662,"askPrice":8.83,"askSize":100,"bidPrice":8.64,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-2.873156,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1765227600000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":8.69,"preHourTrading":{"tag":"盘前","latestPrice":8.75,"preClose":8.69,"latestTime":"09:21 EST","volume":225,"amount":1957.7499749999997,"timestamp":1765203695964},"postHourTrading":{"tag":"盘后","latestPrice":8.93,"preClose":8.69,"latestTime":"19:26 EST","volume":1031,"amount":9204.01,"timestamp":1764980775866},"volumeRatio":0.503381},"requestUrl":"/m/hq/s/CRVO/tweets","defaultTab":"tweets","newsList":[{"id":"2589843914","title":"CervoMed Inc. Files Initial Statement of Beneficial Ownership for Director David Quigley","url":"https://stock-news.laohu8.com/highlight/detail?id=2589843914","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589843914?lang=en_us&edition=fundamental","pubTime":"2025-12-06 07:15","pubTimestamp":1764976528,"startTime":"0","endTime":"0","summary":"CervoMed Inc. has filed an initial statement of beneficial ownership  with the U.S. Securities and Exchange Commission. The filing names David Quigley as a director of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 05, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDLbzHTBf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRVO"],"gpt_icon":0},{"id":"2589790830","title":"CervoMed Inc - to Initiate Phase 3 Trial in Dlb Patients in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2589790830","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589790830?lang=en_us&edition=fundamental","pubTime":"2025-12-05 06:00","pubTimestamp":1764885636,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nFWN3XA0OM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CRVO"],"gpt_icon":0},{"id":"2589858663","title":"CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies","url":"https://stock-news.laohu8.com/highlight/detail?id=2589858663","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589858663?lang=en_us&edition=fundamental","pubTime":"2025-12-05 06:00","pubTimestamp":1764885600,"startTime":"0","endTime":"0","summary":"Phase 2b trial showed significant improvements on primary and key secondary outcomes measures, most prominently in patients without AD co-pathology Significant reduction in key neurodegeneration bioma","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/04/3200383/0/en/CervoMed-Announces-Late-Breaking-Data-at-the-18th-CTAD-Conference-Demonstrating-Neflamapimod-Significantly-Slows-Clinical-Progression-in-Dementia-with-Lewy-Bodies.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO"],"gpt_icon":0},{"id":"2588056973","title":"CervoMed Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2588056973","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588056973?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:55","pubTimestamp":1764683700,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRVO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 02, 2025 08:55 ET (13:55 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO"],"gpt_icon":0},{"id":"2588303097","title":"CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2588303097","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588303097?lang=en_us&edition=fundamental","pubTime":"2025-12-02 20:00","pubTimestamp":1764676800,"startTime":"0","endTime":"0","summary":"1st of two presentations with results from Phase 2b study of neflamapimod at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference Data demonstrates neflamapimod treatment led to significa","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/02/3197738/0/en/CervoMed-Presents-New-Plasma-Biomarker-Data-That-Indicates-Neflamapimod-Broadly-Improves-Neuroinflammation-and-Neurodegeneration-in-Dementia-with-Lewy-Bodies-DLB.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2413666699.HKD","BK4132","LU0205194284.USD","LU0347712357.USD","LU2413666426.HKD","IE00BN0W2T93.GBP","LU0240877869.USD","BK4121","LU1543694498.USD","LU2041044095.USD","CRVO","LU0345774631.USD","IE00BN0W2W23.USD","BK4139","DLB","LU0348723411.USD","BK4097","LU0205193047.USD","AD","LU1721428933.USD","A","BK4588","LU2089279066.USD","LU2092937221.SGD","BK4585","LU0345774391.USD","LU1165135440.EUR","LU2229751404.USD","BK4567","LU0240878834.USD","IE00BN0W2V16.EUR"],"gpt_icon":0},{"id":"2585951461","title":"CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2585951461","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585951461?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:00","pubTimestamp":1763985600,"startTime":"0","endTime":"0","summary":"Late-breaking oral presentation by a leading global authority in Dementia with Lewy bodies (DLB) to highlight updated data from Phase 2b study on neflamapimod treatment for DLB New data demonstrating ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/24/3193345/0/en/CervoMed-to-Share-New-Data-on-Neflamapimod-as-a-Treatment-for-Dementia-with-Lewy-Bodies-at-the-18th-Clinical-Trials-on-Alzheimer-s-Disease-CTAD-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","LU0205193047.USD","LU0345774391.USD","BK4205","LU0205194284.USD","BK4139","UK","AD","BK4233","DLB","LU0240877869.USD","CRVO","LU0240878834.USD","LU0348723411.USD","BK4097","LU0345774631.USD","BK4528"],"gpt_icon":0},{"id":"2584905539","title":"CervoMed Executives Make Bold Moves with Major Stock Purchases!","url":"https://stock-news.laohu8.com/highlight/detail?id=2584905539","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584905539?lang=en_us&edition=fundamental","pubTime":"2025-11-20 10:15","pubTimestamp":1763604913,"startTime":"0","endTime":"0","summary":"New insider activity at CervoMed ( ($CRVO) ) has taken place on November 19, 2025. In a significant show of confidence, key executives at CervoMed ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/cervomed-executives-make-bold-moves-with-major-stock-purchases-insider-trading?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/cervomed-executives-make-bold-moves-with-major-stock-purchases-insider-trading?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CRVO"],"gpt_icon":0},{"id":"2584949388","title":"CervoMed Chief Commercial and Business Officer Matthew Winton Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2584949388","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584949388?lang=en_us&edition=fundamental","pubTime":"2025-11-19 20:46","pubTimestamp":1763556403,"startTime":"0","endTime":"0","summary":"Matthew Winton, Chief Commercial and Business Officer, reported the acquisition of common shares of CervoMed Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 19, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nNDL4ZDbPK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"CervoMed Chief Commercial and Business Officer Matthew Winton Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO","BK4139"],"gpt_icon":0},{"id":"2584962923","title":"Director and 10% Owner Sylvie Gregoire Acquires Common Shares of Cervomed Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2584962923","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584962923?lang=en_us&edition=fundamental","pubTime":"2025-11-17 22:02","pubTimestamp":1763388169,"startTime":"0","endTime":"0","summary":"Sylvie Gregoire, a Director and 10% Owner of CervoMed Inc., reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 17, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL75WG4s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRVO"],"gpt_icon":0},{"id":"2584629471","title":"CervoMed CEO John J. Alam Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2584629471","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584629471?lang=en_us&edition=fundamental","pubTime":"2025-11-17 22:02","pubTimestamp":1763388127,"startTime":"0","endTime":"0","summary":"John J. Alam, CEO and President of Cervomed Inc., reported the acquisition of common shares of Cervomed Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 17, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL35bp8Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"CervoMed CEO John J. Alam Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO","BK4139"],"gpt_icon":0},{"id":"2583542059","title":"CervoMed Executives Make Bold Moves with Significant Stock Purchases!","url":"https://stock-news.laohu8.com/highlight/detail?id=2583542059","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583542059?lang=en_us&edition=fundamental","pubTime":"2025-11-14 10:11","pubTimestamp":1763086310,"startTime":"0","endTime":"0","summary":"New insider activity at CervoMed ( ($CRVO) ) has taken place on November 13, 2025. In a notable series of transactions, key executives at CervoMed ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/cervomed-executives-make-bold-moves-with-significant-stock-purchases-insider-trading?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/cervomed-executives-make-bold-moves-with-significant-stock-purchases-insider-trading?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO","BK4139"],"gpt_icon":0},{"id":"2583593095","title":"CervoMed CFO William Robert Elder Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2583593095","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583593095?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:52","pubTimestamp":1763041963,"startTime":"0","endTime":"0","summary":"William Robert Elder, CFO, GC & Secretary of Cervomed Inc., reported the acquisition of common shares of Cervomed Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 13, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL7g3wgh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"CervoMed CFO William Robert Elder Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRVO"],"gpt_icon":0},{"id":"2582908863","title":"CervoMed’s Strategic Advancements and Clinical Trial Developments Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2582908863","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582908863?lang=en_us&edition=fundamental","pubTime":"2025-11-12 05:16","pubTimestamp":1762895763,"startTime":"0","endTime":"0","summary":"In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on CervoMed, with a price target of $20.00. Soumit Roy has given h...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/cervomeds-strategic-advancements-and-clinical-trial-developments-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/cervomeds-strategic-advancements-and-clinical-trial-developments-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO"],"gpt_icon":0},{"id":"2582366766","title":"CervoMed Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2582366766","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582366766?lang=en_us&edition=fundamental","pubTime":"2025-11-11 20:33","pubTimestamp":1762864380,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRVO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 11, 2025 07:33 ET (12:33 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO"],"gpt_icon":0},{"id":"2582236659","title":"Canaccord Genuity Sticks to Their Buy Rating for CervoMed (CRVO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582236659","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582236659?lang=en_us&edition=fundamental","pubTime":"2025-11-11 20:19","pubTimestamp":1762863554,"startTime":"0","endTime":"0","summary":"In a report released today, Sumant Kulkarni from Canaccord Genuity reiterated a Buy rating on CervoMed, with a price target of $27.00. Kulkarni cov...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-sticks-to-their-buy-rating-for-cervomed-crvo-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-sticks-to-their-buy-rating-for-cervomed-crvo-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO"],"gpt_icon":0},{"id":"2582804707","title":"CervoMed price target lowered to $19 from $20 at Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2582804707","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582804707?lang=en_us&edition=fundamental","pubTime":"2025-11-11 03:35","pubTimestamp":1762803322,"startTime":"0","endTime":"0","summary":"Roth Capital analyst Boobalan Pachaiyappan lowered the firm’s price target on CervoMed (CRVO) to $19 from $20 and keeps a Buy rating on the shares....","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cervomed-price-target-lowered-to-19-from-20-at-roth-capital-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cervomed-price-target-lowered-to-19-from-20-at-roth-capital-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO"],"gpt_icon":0},{"id":"2582751998","title":"CervoMed Q3 EPS $(0.84) Misses $(0.49) Estimate, Sales $322.569K Miss $1.300M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2582751998","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582751998?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:21","pubTimestamp":1762777270,"startTime":"0","endTime":"0","summary":"CervoMed (NASDAQ:CRVO) reported quarterly losses of $(0.84) per share which missed the analyst consensus estimate of $(0.49) by 72.13 percent. This is a 52.73 percent decrease over losses of $(0.55) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48748494/cervomed-q3-eps-0-84-misses-0-49-estimate-sales-322-569k-miss-1-300m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO"],"gpt_icon":0},{"id":"2582587308","title":"CervoMed Q3 net loss widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2582587308","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582587308?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:09","pubTimestamp":1762776576,"startTime":"0","endTime":"0","summary":"CervoMed Q3 net loss widensOverviewCervoMed Q3 2025 net loss of $7.7 mln misses analyst expectationsCash position decreased to $27.3 mln as of September 30, 2025OutlookCervoMed plans to initiate a glo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nL1N3WM0DA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO","BK4139"],"gpt_icon":0},{"id":"2582587373","title":"CervoMed reports Q3 2025 grant revenue of $0.3 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2582587373","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582587373?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:06","pubTimestamp":1762776360,"startTime":"0","endTime":"0","summary":"CervoMed Inc. reported a cash position of $27.3 million as of September 30, 2025, down from $38.9 million at December 31, 2024. The company stated that its current cash, cash equivalents, and marketable securities are expected to fund operations into the third quarter of 2026. Grant revenue for the third quarter of 2025 was $0.3 million, compared to $1.9 million in the same period of 2024, reflecting the completion of the initial and extension phases of the RewinD-LB trial. During the quarter, CervoMed announced new Phase 2b RewinD-LB trial data and the appointment of Matthew Winton as Chief Commercial and Business Officer, as well as David Quigley to the Board of Directors. Initial biomarker data from a Phase 2a trial in frontotemporal dementia and topline results from a Phase 2a trial in stroke recovery are expected in 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL8bHgRq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO","BK4139"],"gpt_icon":0},{"id":"2582732158","title":"Press Release: CervoMed Reports Third Quarter 2025 Financial Results and Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2582732158","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582732158?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:00","pubTimestamp":1762776000,"startTime":"0","endTime":"0","summary":"Aligned with U.S Food and Drug Administration  on design of planned Phase 3 clinical trial of neflamapimod in patients with dementia with Lewy bodies . Reported 32-week data from Phase 2b RewinD-LB trial showing neflamapimod treatment in patients with DLB had a durable beneficial effect on clinical progression and resulted in substantial reductions in plasma levels of a well-established biomarker of neurodegeneration. Meeting with global regulators in coming months and preparing for global pivotal trial initiation in second half of 2026. Initial biomarker data from Phase 2a trial in a sub-type of frontotemporal dementia  and topline results from Phase 2a trial in recovery after stroke expected in 2026","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0345774631.USD","BK4097","LU0348723411.USD","LU0205194284.USD","AD","LU0345774391.USD","DLB","BK4139","LU0240878834.USD","LU0205193047.USD","LU0240877869.USD","CRVO","BK4132"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cervomed.com","stockEarnings":[{"period":"1week","weight":-0.1258},{"period":"1month","weight":0.1839},{"period":"3month","weight":-0.1732},{"period":"6month","weight":0.1404},{"period":"1year","weight":-0.106},{"period":"ytd","weight":2.7137}],"compareEarnings":[{"period":"1week","weight":0.0034},{"period":"1month","weight":0.012},{"period":"3month","weight":0.0594},{"period":"6month","weight":0.1445},{"period":"1year","weight":0.1303},{"period":"ytd","weight":0.17}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":0.064666},{"month":2,"riseRate":0.555556,"avgChangeRate":0.120404},{"month":3,"riseRate":0.555556,"avgChangeRate":0.363667},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.064048},{"month":5,"riseRate":0.444444,"avgChangeRate":0.146641},{"month":6,"riseRate":0.111111,"avgChangeRate":-0.121539},{"month":7,"riseRate":0.222222,"avgChangeRate":-0.07795},{"month":8,"riseRate":0.666667,"avgChangeRate":0.076308},{"month":9,"riseRate":0.111111,"avgChangeRate":-0.117703},{"month":10,"riseRate":0.111111,"avgChangeRate":-0.039339},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.045938},{"month":12,"riseRate":0.3,"avgChangeRate":-0.198086}],"exchange":"NASDAQ","name":"CervoMed","nameEN":"CervoMed"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CervoMed(CRVO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CervoMed(CRVO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CervoMed,CRVO,CervoMed股票,CervoMed股票老虎,CervoMed股票老虎国际,CervoMed行情,CervoMed股票行情,CervoMed股价,CervoMed股市,CervoMed股票价格,CervoMed股票交易,CervoMed股票购买,CervoMed股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CervoMed(CRVO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CervoMed(CRVO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction